These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 12001705)
1. Non-myeloblative stem-cell transplantation for immunotherapy of cancer and non-malignant diseases with allogeneic lymphocytes. Slavin S Isr Med Assoc J; 2002 Apr; 4(4):284-7. PubMed ID: 12001705 [No Abstract] [Full Text] [Related]
2. Non-myeloablative stem-cell transplantation in the treatment of malignant and non-malignant disorders. Shimoni A; Nagler A Isr Med Assoc J; 2002 Apr; 4(4):272-9. PubMed ID: 12001702 [No Abstract] [Full Text] [Related]
5. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy. Talmadge JE Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168 [TBL] [Abstract][Full Text] [Related]
6. Immunotherapy in allogeneic hematopoietic stem cell transplantation--not just a case for effector cells. Troeger A; Meisel R; Moritz T; Dilloo D Bone Marrow Transplant; 2005 Mar; 35 Suppl 1():S59-64. PubMed ID: 15812533 [TBL] [Abstract][Full Text] [Related]
7. [Alloreactive donor lymphocytes (DLI) after allogeneic hematopoietic stem cell transplantation (HSCT): study of toxicity and efficacy]. Michallet AS; Nicolini F; Michallet M Bull Cancer; 2003; 90(8-9):758-62. PubMed ID: 14609766 [TBL] [Abstract][Full Text] [Related]
8. Immunotherapy by allogeneic stem cell transplantation. Ringdén O Adv Cancer Res; 2007; 97():25-60. PubMed ID: 17419940 [TBL] [Abstract][Full Text] [Related]
9. Reduced-intensity conditioning for the treatment of malignant and life-threatening non-malignant disorders. Slavin S; Aker M; Shapira MY; Resnick I; Bitan M; Or R Clin Transpl; 2003; ():275-82. PubMed ID: 15387119 [TBL] [Abstract][Full Text] [Related]
10. A comparison between low intensity and reduced intensity conditioning in allogeneic hematopoietic stem cell transplantation for solid tumors. Conrad R; Remberger M; Cederlund K; Ringdén O; Barkholt L Haematologica; 2008 Feb; 93(2):265-72. PubMed ID: 18245651 [TBL] [Abstract][Full Text] [Related]
11. Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases. Resnick IB; Shapira MY; Slavin S Transpl Immunol; 2005 Aug; 14(3-4):207-19. PubMed ID: 15982565 [TBL] [Abstract][Full Text] [Related]
13. Cytolytic pathways in haematopoietic stem-cell transplantation. van den Brink MR; Burakoff SJ Nat Rev Immunol; 2002 Apr; 2(4):273-81. PubMed ID: 12001998 [TBL] [Abstract][Full Text] [Related]
14. Improving immune reconstitution while preventing GvHD in allogeneic stem cell transplantation. André-Schmutz I; Dal Cortivo L; Fischer A; Cavazzana-Calvo M Cytotherapy; 2005; 7(2):102-8. PubMed ID: 16040389 [TBL] [Abstract][Full Text] [Related]
15. [Allogeneic hematopoietic stem cell transplantation for solid tumors]. Kanda Y Rinsho Ketsueki; 2004 Mar; 45(3):189-94. PubMed ID: 15103931 [No Abstract] [Full Text] [Related]
16. Expansion of antileukaemia CTL lines and clones for adoptive cell therapy in paediatric patients given allogeneic haematopoietic stem cell transplantation. Montagna D; Maccario R; Locatelli F Int J Immunogenet; 2008 Aug; 35(4-5):389-93. PubMed ID: 18976444 [TBL] [Abstract][Full Text] [Related]
17. [Minor antigens - major impact. The role of minor histocompatibility antigens in allogeneic hematopoietic stem cell transplantation]. Hudecek M; Bartsch K; Tschiedel S; Niederwieser D Dtsch Med Wochenschr; 2008 Jul; 133(28-29):1511-6. PubMed ID: 18597211 [TBL] [Abstract][Full Text] [Related]
18. [The molecular characteristics of T-cell immune reconstitution in leukemia patients after allogeneic hematopoietic stem cell transplantation]. Fu YW; Wu DP; Sun AN; Feng YF; Chang WR; Zhu ZL; Zhu P Zhonghua Xue Ye Xue Za Zhi; 2007 May; 28(5):312-7. PubMed ID: 17877159 [TBL] [Abstract][Full Text] [Related]
19. Recent molecular and cellular advances in pediatric bone marrow transplantation. Talano JA; Margolis DA Pediatr Clin North Am; 2006 Aug; 53(4):685-98. PubMed ID: 16872999 [TBL] [Abstract][Full Text] [Related]